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Introduction
A majority of currently used drugs display, in addition to the
therapeutic action, definite side effects which are often severe and
unpredictable; the difference between the therapeutic and
harmful dose may be quite small. This may necessitate monitoring
drug concentration in the patient’s serum, which is cumbersome
and increases the cost of treatment [9]. In light of the recent
literature of the subject, a search for substances which augment
the therapeutic efficacy of existing drugs may prove equally
fruitful as the development of the new ones. Drug delivery systems
(DDS) which include many different conjugates, such as polymeric
micelles, liposomes, hybrid carriers and polyplexes (complexes of
the polymer–DNA type) [1,4] may provide better penetration of
drugs across biologicalmembraneswhich results in faster access to
the interior of cells and, in general, to areas distant from the lumen
of blood vessels. Currently, liposomal formulationswhich facilitate
the penetration through biological membranes are widely used as
carriers of pharmacologically active substances [24]. Cationic
lipids of various structures have been suggested to enhance the
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A B S T R A C T
Background: The unpredictable side effects of amajority currently used drugs are the substantial issue, in
which patients and physicians are forced to deal with. Augmenting the therapeutic efficacy of drugs may
prove more fruitful than searching for the new ones. Since recent studies show that new cationic
derivatives of polyisoprenoid alcohols (APrens) might exhibit augmenting properties, we intend to use
them as a component of liposomal drug carriers. In this study we investigate if these compounds do not
per se cause untoward effects on the living organism.
Methods: Male Sprague–Dawley rats received for four weeks daily injections (0.5 ml sc) of liposomes
built of dioleoyl phosphatidylethanolamine (DOPE), liposomes built of DOPE and APren-7 (ratio 10:1) or
water solvent. Weekly, rats were observed in metabolic cages (24 h); blood and urine were sampled for
analysis; body weight (BW) and systolic blood pressure (SBP) were determined. After chronic
experiment, kidneys and heart were harvested for histological and morphometric analysis.
Results: The 4-week BW increments were in the range of 97  4 to 102  4%, intergroup differences were
not significant. Microalbuminuria was the lowest in the group receiving liposomes with APren-7
(0.22  0.03 mg/day). Water and food intake, plasma and urine parameters were similar in all groups.
Conclusions: Newly designed liposomes containing APren-7 did not affect functions of the excretory and
cardiovascular systems, and renal morphology; therefore we find them suitable as a component of
liposomal drug carriers.
 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp.
z o.o. All rights reserved.
Abbreviations: APren, cationic derivative of polyisoprenoid alcohol; BW, body
weight; DDS, drug delivery systems; DOPE, dioleoyl phosphatidylethanolamine;
DPPC, dipalmitoylphosphatidylcholine; Ht, haematocrit; LV/BW, left ventricular –
to – body weight ratio; NO, nitric oxide; NOx, excretion of nitric oxide metabolites;
PE, phosphatidylethanolamine; PNa, plasma sodium concentration; Posm, plasma
osmolality; SBP, systolic blood pressure; sc, subcutaneously; UAE, urinary albumin
excretion; UK, concentration of potassium in urine; UNa, concentration of sodium in
urine; Uosm, urine osmolality.
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efficacy of liposomal drug and nucleic acids delivery [14,21].
Recent studies show that cationic derivative of polyprenol
tentatively named APren, new semi-synthetic derivative of
polyisoprenoid alcohol, might be successfully used as component
of liposomal formulas used for lipofection [18].
Polyprenolsare linearpolymersbuilt of5upto150 isopreneunits.
Their postulated cellular functions comprise involvement in cell
response to environmental stress [26]. It is known that polyprenols
and their phosphorylated derivatives increase the permeability and
fluidity of model membranes and intensify the fusion of model
membranes [26]. A new type of semi-synthetic cationic polyisopre-
noid derivatives has been obtained recently. Taking advantage of
their lipofecting properties [18] new drug carriers based on
liposomes containing these derivatives of polyisoprenoid alcohols
weredesigned. Fromamongvariousnaturally occurringpolyprenols,
the one containing seven isoprene units was subjected to chemical
modifications to obtain heptaprenyltrimethylammonium iodide
(APren-7), to be used as a component of liposomal drug carrier.
Our aim was to investigate if this compound does not per se cause
untoward effects on the living organism.
Among mammalian organs and tissues the kidneys are known
to be particularly sensitive to drug-dependent toxicity which may
damage the renal glomeruli and various structures and tissues
located in the renal medulla, such as local tubule fragments,
interstitium and vasa recta. The vulnerability of the medulla
obviously depends on the usual process of concentration of
numerous substances, including various drugs, which occurs in
this region. In this studywe focused on potential changes in kidney
structure and function but also examined some indices of general
health and behaviour (e.g.weight gain, activity) as well as selected
status indices of the cardiovascular system.
The impact of APren-7 on living organisms was studied in male
Sprague–Dawley rats; animals aged 5–6 weeks were used to
determine, in addition, the possible influence of APren-7 on the
development andmaturation. Effects of subcutaneous injections of
liposomes containing APren-7 were compared with those of
liposomes built exclusively of commonly used dioleoyl phospha-
tidylethanolamine (DOPE), and those seen in rats receiving water
solvent for liposome solutions.
Materials and methods
Preparation of heptaprenyltrimethylammonium iodide (APren-7)
This compoundwas obtained bymodification of polyisoprenoid
alcohols derived from birch wood following the procedure
described earlier [18].
Preparation of liposomal suspensions for injection
Liposomal suspensions were prepared using lipid film hydration
protocol. Briefly, to obtain classical liposomes (L), 55ml of a solution
of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, Sigma)
in chloroform (90 mg/ml) was dried by stream of nitrogen gas to
forma thinfilmon the bottomof the glass tube. The filmwas further
dried by exsiccation under reduced pressure, overnight. Thenwater
was added to hydrate the film and multilamellar liposomes were
formed by vortexing each tube for at least 8 min. The obtained
suspensionwas extruded few times through a 100 nmmembrane to
obtain unilamellar liposomes (LiposoFast extruder, Avestin Europe
GmbH, Mannheim, Germany).
To obtain liposomes with APren-7 (L + P), 50 ml of a solution of
DOPE in chloroform (90 mg/ml) and 25 ml of a solution of APren-7
in chloroform (18 mg/ml) were mixed together (DOPE:APren-7
molar ratio 10:1) and then the procedure of further preparation
was as described above.
Experimental animals
The experimental procedures were approved by the IV Ethical
Committee, Warsaw. Male Sprague–Dawley rats, weighing
154  3 g at the start of experiments, were fed ad libitum a standard
diet (STD, 0.25% Na w/w, SSNIFF GmbH, Soest, Germany) and had free
access to drinking water during the whole experiment. The animals
were accustomed to the housing and measurement procedures
during the week preceding the experiments. This was done to
eliminate the stress associated with immobilization needed to
measure systolic blood pressure (SBP); such stress is known to
increase SBP per se.
Experimental protocols and measurements
During four weeks three groups of rats received daily injections
(0.5 ml, sc) of freshly prepared solutions of classical liposomes (L,
n = 13), liposomes with APren-7 (L + P, n = 13, 12 mg/kg), or water
solvent (W, n = 12). At one-week intervals rats were placed for 24 h
in metabolic cages (Tecniplast S.p.A. Buguggiate, Italy) to measure
food and water intake, the weight of faeces, and urine volume and
osmolality (Uosm), as well as the concentration of sodium (UNa),
potassium (UK), albumin and nitric oxide metabolites. Also
determined were body weight (BW) and SBP (tail-cuff method,
Coda System, Kent Scientific Corporation, Connecticut, USA); blood
was sampled for plasma osmolality (Posm), plasma sodium
concentration (PNa) and haematocrit (Ht). In the end of the
experiment all animals were anesthetized with intraperitoneal
sodium thiopental (Sandoz GmbH, Kundl, Austria), 100 mg/kg, and
the samples of the kidneys (for morphometric and histologic
studies) and of the heart (for morphometric examination only)
were harvested.
Analytical procedures
Urine volume was determined by gravimetric method, plasma
and urine osmolality by freezing point depression (Osmomat1
030 M, Gonotec, Berlin, Germany), sodium and potassium concen-
tration by flame photometry (PFP7/C, Jenway Ltd, Stone, UK),
nitrites/nitrates using nitric oxide (total) detection kit (Enzo Life
Sciences Inc., New York, USA), and albumin content using UAE
immunoperoxidase assay for determination of albumin in rat
samples (Immunology Consultants Laboratory, Inc., Portland, USA).
Statistics
Data are presented as means  SEM. The significance of changes
was evaluated by multivariate analysis of variance (ANOVA) with
repeated measurements, followed by Newman–Keuls post hoc test
(STATISTICA, version 10.0, StatSoft Inc.). The 4-week increments in
the parameters measured were compared between groups by one-
way ANOVA. The level of statistical significance was set at of p < 0.05.
Results
Body weight profiles over 4 weeks are shown in Fig. 1. The
increase of the body mass was almost parallel for all three groups
of animals analyzed. When expressed as per cent of the starting
weight value (unlike in Fig. 1. where absolute values are given), the
curves for L, L + P andW groups were superimposable. The 4-week
BW increments were 109  4, 97  4 and 102  4% in the respective
groups (intergroup differences not significant).
Water and food intake, faeces weight, and urine volume, total
solute, sodium and potassium excretion in four consecutive weeks
are presented in Table 1. For most of the parameters measured the
starting values (week 0) tended to be slightly higher in animals
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receiving water solvent compared to those of the two liposome
treated groups and the differences were maintained throughout
the 4-week observation period. The intergroup differences in total
4-week increments in water intake and urine volume deserve
attention. The increment (D) of water intake was in the two
liposome treated groups distinctly lower than in the W group; the
difference was significant for the L + P group only (last column of
Table 1). On the other hand, the increment of urine volume in
liposome treated groups was higher than in the W group
(difference significant for the L group).
Systolic blood pressure (SBP) slightly increased in each group
during four weeks of observation: in group L from 131  3 to
135  3 mmHg, in L + P from 129  4 to 144  5 mmHg, and in W
from 131  7 to 142  4 mmHg (non-significant, Fig. 2). The
variability of SBP data was relatively high and there were no
significant within-group or inter-group differences.
Plasma osmolality, sodium concentration and blood haemato-
crit did not show significant changes over time (within groups) or
between experimental groups (Table 2).
Urinary albumin excretion (UAE) measurements before treat-
ments and in the last week of observation (Fig. 3) disclosed a
significant increase inW group only; in the fourthweek UAE in this
group was significantly higher than in groups L and L + P.
The excretion of nitric oxidemetabolites (nitrites/nitrates, NOx)
measured before and in the fourthweek of treatments disclosed no
significant within-group (time dependent) or inter-group differ-
ences (Fig. 4).
Left ventricular – to – body weight ratio (LV/BW), measured in
each animal at the end of the experiments, was the highest in the L
group and significantly different from that in the W but not in the
L + P group (Fig. 5). The values for L and L + P groups were not
significantly different.
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Fig. 1. Four-week profiles of body weight (BW) of rats receiving: L – liposomes built
of DOPE (n = 13), L + P – liposomes built of DOPE and APren-7 (n = 13), W – water
(n = 12).
[(Fig._2)TD$FIG]
100
110
120
130
140
150
160
0 1 2 3 4
weeks
L
L+P
W
SB
P
(m
m
H
g)
Fig. 2. Four-week profiles of systolic blood pressure (SBP) in rats receiving: L –
liposomes built of DOPE (n = 8), L + P – liposomes built of DOPE and APren-7 (n = 8),
W – water (n = 8).
Table 1
Four-week profiles of daily water and food intake, urine volume, total solute, sodium and potassium excretion in the three groups.
Group Weeks D
0–4
0 1 2 3 4
Water intake (ml/24h) L 211 232 231 251 272 62
L+P 241 251 271 262 292 42*
W 231 271 291 301 373 133
Food intake (g/24h) L 14.2 0.8 16.31.0 17.2 0.8 18.5 0.5 19.10.9 6.21.1
L +P 16.0 0.7 16.91.0 17.91.7 16.2 0.7 19.91.0 3.91.2
W 17.2 0.5 18.80.7 20.21.3 22.3 0.7 21.40.9 4.31.0
Faeces weight (g/24) L 5.1 0.4 7.20.8 6.7 0.8 7.8 0.7 7.20.7 2.10.8
L +P 5.6 0.5 7.40.7 7.1 0.6 7.4 0.6 9.20.6 3.60.8
W 6.8 0.5 8.50.5 8.4 0.7 9.0 0.6 10.70.6 3.90.8
Urine volume (ml/24h) L 5.1 0.4 7.90.8 7.3 0.7 9.0 0.6 10.90.6 5.80.5*
L +P 6.1 0.7 8.10.4 9.0 0.6 9.11.0 12.10.9 6.01.1
W 7.0 0.5 9.00.6 8.4 0.6 10.0 0.6 11.00.5 3.90.6
Total solutes (mosm/24h) L 12.5 0.6 17.00.9 16.7 0.8 20.0 0.7 22.00.8 9.51.1
L +P 12.81.0 17.10.5 17.5 0.6 18.1 0.7 21.80.7 9.01.5
W 16.1 0.5 20.10.4 20.51.0 22.7 0.9 24.30.5 8.20.9
Na+ (mmol/24h) L 0.7 0.0 1.10.1 1.0 0.1 1.3 0.1 1.40.1 0.70.1
L +P 0.5 0.1 0.80.1 0.9 0.1 1.0 0.1 1.20.1 0.70.1
W 0.9 0.0 1.30.1 1.5 0.1 1.4 0.1 1.60.1 0.70.1
K+ (mmol/24h) L 3.1 0.2 4.00.2 3.5 0.2 4.3 0.1 4.60.2 1.50.2
L +P 3.2 0.3 3.80.1 3.6 0.1 3.8 0.2 4.20.1 1.00.3
W 4.0 0.1 4.80.1 4.7 0.2 4.7 0.2 4.90.2 1.00.2
Values are means SEM; L – rats receiving liposomes (n =13), L + P – liposomes with APren-7 (n =13), W – water solvent (n =12).
* p<0.05 vs. W group.
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Renal cortical andmedullary tissuewere harvested at the end of
experiments and the slices were stained with haematoxylin–eosin
(Fig. 6). There were no explicit signs of tissue damage in any
experimental group. Nor were there any inter-group differences in
the microscopic images of the renal cortex and medulla.
Discussion
Over the past decade, liposomal drug delivery systems were
used by many researchers and various applications were reported,
such as targeted gene therapy [11,25], transfollicular [15] or
ophthalmic [20] drug delivery. In many cases DOPE (dioleoyl
phosphatidylethanolamine), an analogue of the native PE with a
defined fatty acid composition, was used in liposomal formula-
tions. Due to its fusogenic properties DOPE is considered as
valuable component of the lipofecting formulas. DOPE is not
considered as toxic per se, however it has been shown to enhance
the toxicity of various cationic lipids tested in the cell-line models
since the replacement of DOPE by dipalmitoylphosphatidylcholine
(DPPC) significantly reduced liposome toxicity towards macro-
phages [6]. Subsequently, new derivative of polyisoprenoid
alcohol, the APren, was investigated in cell-line model [18] as
potential component of liposomal drug carriers. A literature search
shows that possible untoward effects of these compounds have
never been tested before, therefore in the present studywe address
this issue, focusing on the impact of APren on some functional and
morphologic features of the cardiovascular and renal excretory
system of normal Sprague–Dawley rats.
All studied animals were in good health and displayed normal
physical activity. In general, the parameters measured in the two
groups receiving liposomes (the classical liposomes built of DOPE
and the newly designed liposomes with DOPE and APren-7) were
more similar to each other than to the group (W) receiving water
solvent. There were no differences between groups regarding food
intake, the renal excretion of total solute, sodiumand potassium, or
plasma osmolality and sodium concentration, and blood haema-
tocrit.
It should be noted that the apparent between-group difference
in absolute values of BW (Fig. 1) depended on higher baseline BW
in the W group, obviously a matter of imperfect randomization of
animals. Overall, the differences between groups were small and
Table 2
Four-week profiles of plasma osmolality and sodium concentration and blood haematocrit.
Group Weeks
0 1 2 3 4
Plasma osmolality (mosm/l) L 3023 2992 3002 3061 3061
L+P 3042 3012 3062 3102 3102
W 3001 3022 3071 3092 3073
Plasma sodium concentration (mmol/l) L 1362 1392 1332 1322 1331
L+P 1301 1361 1322 1373 1292
W 1323 1342 1352 1312 1352
Haematocrit (%) L 401 411 430 441 431
L+P 40 0 411 421 441 421
W 401 411 441 441 441
Values are means SEM; rats receiving: L – liposomes (n =13), L + P – liposomes with APren-7 (n =13), W – water solvent (n =12).
[(Fig._3)TD$FIG]
0,0
0,2
0,4
0,6
0,8
40
UA
E
(m
g/
24
h) *
# 
weeks 
Fig. 3. Urinary albumin excretion (UAE, means  SEM) before and after 4 weeks of
observation in rats receiving: & L – liposomes (n = 7), & L + P – liposomes with
APren-7 (n = 7), [TD$INLINE] W – water solvent (n = 6); *p < 0.05 vs. day ‘‘0’’; #p < 0.05 vs.
concurrent values in L and L + P groups.
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Fig. 4.Urinary excretion of nitric oxidemetabolites (UNOxV,means  SEM)& before
and & after four weeks of observation in rats receiving: L – liposomes (n = 7), L + P –
liposomes with APren-7 (n = 6), W – water solvent (n = 6).
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Fig. 5. Left ventricular weight to body weight ratio after 4 weeks of observation rats
receiving:& L – liposomes (n = 13),& L + P – liposomes with APren-7 (n = 13), [TD$INLINE] W
– water solvent (n = 16); *p < 0.05 vs. W (one-way ANOVA followed by Newman–
Keuls post hoc test).
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the values for L, L + P and W groups expressed as per cent of the
starting weight were almost identical. According to Maitani et al.
[19] the liposomes composed of dipalmitoylphosphatidylcholine
(DPPC) do not cause any changes per se in the rat’s body weight
after subcutaneous injection. To the best of our knowledge
physiological effects of any PE analogue treatment has never been
tested in animals before.
The profiles of water intake and urine excretion deserve some
attention (Table 1), especially the observation that the four-week
increment (D) of water intake was in the W group higher than in
both liposome groups whereas the increment in urine output in the
W group was the lowest. For some reason the liposome-treated rats
wereprotected against anywater retention showing abetter balance
of water intake and output compared to solvent-treated rats.
SBP tended to increase in all groups (Fig. 2), however, the changes
were minor and physiologically meaningless. The increasing
tendency may have been related to daily subcutaneous injections,
blood sampling and the distress due to the tail cuff method of SBP
measurement, which requires immobilization of animals; the pro-
hypertensive role of such manoeuvres has been described before
[12]. It is unlikely that the minor SBP changes could induce left
ventricular hypertrophy, measured as LV/BW which is a sensitive
index of hypertension or heart disease [7]. Nor did liposome
treatment affect this index in some direct way: LV/BW values for all
groupswere in the normal range for normotensive Sprague–Dawley
rats [10] and so were also the values of plasma osmolality, sodium
concentration and blood haematocrit. On the whole, there were no
signs indicating damage of the cardiovascular system.
Various drugs and active substances are known to cause a
number of morphologic changes in renal structures, such as
microvacuolization (vacuolar lesions) [23]; cell loss, tubular
dilation or disruption of the brush border of proximal tubules
[5], atrophy of glomeruli or patches of necrosis [22]. All these
abnormalities are likely to impair renal function. However,
inspection of renal tissue slices stained with haematoxylin–eosin
did not reveal any damage that might be caused by administration
of the tested substances; microscopic images of the renal cortex
and medulla did not differ between groups.
Microalbuminuria (elevated urinary albumin excretion, UAE) is
a good marker of kidney damage and malfunction, and is also
considered as an early index of cardiovascular disease [8,27,30]. In
the end of experiments the values (Fig. 3) were within the normal
UAE range for healthy Sprague–Dawley rats (0–1 mg/day) [16,17],
which speaks against any kidney or cardiovascular system
dysfunction. Since UAE significantly increased in the W but not
in L or L + P group, one could speculate that liposomes possess
some protective properties.
Nitric oxide (NO) is an important antioxidant signalling
molecule, which plays a critical role in various biological processes,
such as control of vascular tone, blood pressure, renal haemody-
namic and excretion, as well as developmental functions [3,13].
The actual activity of NO, which is produced by nitric oxide
synthases (NOS) in many tissues, can be estimated by measuring
the excretion of its metabolites [28]. However, the excretion of
nitrites/nitrates (NOx) was almost stable throughout experiments
and did not depend on the treatment applied (Fig. 5). Bentinger
et al. [2] suggested that other derivatives of polyisoprenoids
(epoxides) exhibit some beneficial activity, possibly by increasing
the cell antioxidant capacity due to the stimulation of the
biosynthesis of coenzyme Q, a molecule likely to protect nitric
oxide against inactivation by free radicals [29]. However, in this
study we found no indication of antioxidant properties of APren-7.
The newly designed liposomes containing APrens did not affect,
after subcutaneous administration, the development and matura-
tion, or the function of the cardiovascular and renal excretory
system of normal Sprague–Dawley rats. Since, microalbuminuria
was even lower in the two groups receiving liposomes compared to
that receiving water solvent, one can speculate on some protective
action of liposomes, a proposal which would require further
investigation. In general, our results showed no explicit adverse
influence of the newly designed liposomes. In particular, theywere
not found to cause any damage per se of the rats’ cardiovascular or
renal excretory system, therefore we find them suitable as a
component of liposomal drug carriers.
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